![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PIK3C2A |
Gene summary for PIK3C2A |
![]() |
Gene information | Species | Human | Gene symbol | PIK3C2A | Gene ID | 5286 |
Gene name | phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha | |
Gene Alias | CPK | |
Cytomap | 11p15.1 | |
Gene Type | protein-coding | GO ID | GO:0001525 | UniProtAcc | L7RRS0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5286 | PIK3C2A | CA_HPV_1 | Human | Cervix | CC | 6.53e-06 | -1.53e-01 | 0.0264 |
5286 | PIK3C2A | CCI_2 | Human | Cervix | CC | 3.70e-03 | 6.92e-01 | 0.5249 |
5286 | PIK3C2A | AEH-subject1 | Human | Endometrium | AEH | 8.73e-13 | 3.69e-01 | -0.3059 |
5286 | PIK3C2A | AEH-subject2 | Human | Endometrium | AEH | 8.04e-03 | 1.58e-01 | -0.2525 |
5286 | PIK3C2A | AEH-subject3 | Human | Endometrium | AEH | 9.80e-08 | 2.33e-01 | -0.2576 |
5286 | PIK3C2A | AEH-subject4 | Human | Endometrium | AEH | 9.11e-03 | 2.02e-01 | -0.2657 |
5286 | PIK3C2A | AEH-subject5 | Human | Endometrium | AEH | 5.05e-22 | 5.73e-01 | -0.2953 |
5286 | PIK3C2A | EEC-subject1 | Human | Endometrium | EEC | 1.00e-15 | 4.39e-01 | -0.2682 |
5286 | PIK3C2A | EEC-subject2 | Human | Endometrium | EEC | 5.76e-10 | 3.39e-01 | -0.2607 |
5286 | PIK3C2A | EEC-subject3 | Human | Endometrium | EEC | 4.94e-07 | 1.53e-01 | -0.2525 |
5286 | PIK3C2A | EEC-subject5 | Human | Endometrium | EEC | 6.55e-08 | 2.93e-01 | -0.249 |
5286 | PIK3C2A | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 3.26e-12 | 2.46e-02 | -0.1869 |
5286 | PIK3C2A | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 8.76e-15 | 5.56e-02 | -0.1875 |
5286 | PIK3C2A | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 1.45e-14 | 2.47e-03 | -0.1883 |
5286 | PIK3C2A | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 1.15e-10 | 2.01e-02 | -0.1934 |
5286 | PIK3C2A | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 4.91e-20 | 1.04e-01 | -0.1917 |
5286 | PIK3C2A | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 1.06e-18 | 8.07e-02 | -0.1916 |
5286 | PIK3C2A | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 1.37e-02 | 1.06e-01 | -0.1269 |
5286 | PIK3C2A | LZE4T | Human | Esophagus | ESCC | 1.28e-09 | 2.63e-01 | 0.0811 |
5286 | PIK3C2A | LZE5T | Human | Esophagus | ESCC | 9.78e-06 | 4.73e-01 | 0.0514 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000828618 | Thyroid | ATC | insulin receptor signaling pathway | 60/6293 | 116/18723 | 4.20e-05 | 3.40e-04 | 60 |
GO:001059531 | Thyroid | ATC | positive regulation of endothelial cell migration | 67/6293 | 133/18723 | 4.61e-05 | 3.70e-04 | 67 |
GO:001059431 | Thyroid | ATC | regulation of endothelial cell migration | 102/6293 | 232/18723 | 6.17e-04 | 3.51e-03 | 102 |
GO:004826816 | Thyroid | ATC | clathrin coat assembly | 12/6293 | 18/18723 | 4.22e-03 | 1.79e-02 | 12 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0513220 | Cervix | CC | Salmonella infection | 74/1267 | 249/8465 | 1.33e-09 | 2.54e-08 | 1.50e-08 | 74 |
hsa05132110 | Cervix | CC | Salmonella infection | 74/1267 | 249/8465 | 1.33e-09 | 2.54e-08 | 1.50e-08 | 74 |
hsa0513226 | Endometrium | AEH | Salmonella infection | 71/1197 | 249/8465 | 1.69e-09 | 3.44e-08 | 2.52e-08 | 71 |
hsa05132112 | Endometrium | AEH | Salmonella infection | 71/1197 | 249/8465 | 1.69e-09 | 3.44e-08 | 2.52e-08 | 71 |
hsa0513227 | Endometrium | EEC | Salmonella infection | 71/1237 | 249/8465 | 7.11e-09 | 1.30e-07 | 9.69e-08 | 71 |
hsa0513236 | Endometrium | EEC | Salmonella infection | 71/1237 | 249/8465 | 7.11e-09 | 1.30e-07 | 9.69e-08 | 71 |
hsa05132211 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
hsa05132310 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
hsa0513214 | Liver | NAFLD | Salmonella infection | 55/1043 | 249/8465 | 8.48e-06 | 3.09e-04 | 2.49e-04 | 55 |
hsa0513215 | Liver | NAFLD | Salmonella infection | 55/1043 | 249/8465 | 8.48e-06 | 3.09e-04 | 2.49e-04 | 55 |
hsa0513242 | Liver | HCC | Salmonella infection | 178/4020 | 249/8465 | 5.90e-15 | 1.98e-13 | 1.10e-13 | 178 |
hsa0513252 | Liver | HCC | Salmonella infection | 178/4020 | 249/8465 | 5.90e-15 | 1.98e-13 | 1.10e-13 | 178 |
hsa0513216 | Lung | IAC | Salmonella infection | 52/1053 | 249/8465 | 9.46e-05 | 1.28e-03 | 8.50e-04 | 52 |
hsa0513217 | Lung | IAC | Salmonella infection | 52/1053 | 249/8465 | 9.46e-05 | 1.28e-03 | 8.50e-04 | 52 |
hsa0513223 | Lung | AIS | Salmonella infection | 50/961 | 249/8465 | 3.47e-05 | 5.62e-04 | 3.59e-04 | 50 |
hsa0513233 | Lung | AIS | Salmonella infection | 50/961 | 249/8465 | 3.47e-05 | 5.62e-04 | 3.59e-04 | 50 |
hsa0513228 | Prostate | BPH | Salmonella infection | 99/1718 | 249/8465 | 7.26e-13 | 1.50e-11 | 9.27e-12 | 99 |
hsa05132113 | Prostate | BPH | Salmonella infection | 99/1718 | 249/8465 | 7.26e-13 | 1.50e-11 | 9.27e-12 | 99 |
hsa0513229 | Prostate | Tumor | Salmonella infection | 98/1791 | 249/8465 | 2.55e-11 | 5.28e-10 | 3.27e-10 | 98 |
hsa0513237 | Prostate | Tumor | Salmonella infection | 98/1791 | 249/8465 | 2.55e-11 | 5.28e-10 | 3.27e-10 | 98 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PIK3C2A | SNV | Missense_Mutation | c.185N>C | p.Arg62Thr | p.R62T | O00443 | protein_coding | tolerated_low_confidence(0.56) | benign(0.01) | TCGA-AR-A1AJ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PIK3C2A | SNV | Missense_Mutation | novel | c.4297N>T | p.His1433Tyr | p.H1433Y | O00443 | protein_coding | deleterious(0) | possibly_damaging(0.589) | TCGA-AR-A24U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PIK3C2A | SNV | Missense_Mutation | c.742A>T | p.Ile248Leu | p.I248L | O00443 | protein_coding | tolerated_low_confidence(0.5) | benign(0.003) | TCGA-BH-A1FD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
PIK3C2A | SNV | Missense_Mutation | c.4022G>A | p.Gly1341Glu | p.G1341E | O00443 | protein_coding | deleterious(0) | possibly_damaging(0.885) | TCGA-C8-A12K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PIK3C2A | SNV | Missense_Mutation | rs374593257 | c.642N>G | p.Ile214Met | p.I214M | O00443 | protein_coding | tolerated_low_confidence(0.31) | benign(0.021) | TCGA-GM-A3XL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | CR |
PIK3C2A | insertion | Frame_Shift_Ins | novel | c.256_257insA | p.Arg86LysfsTer6 | p.R86Kfs*6 | O00443 | protein_coding | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
PIK3C2A | deletion | Frame_Shift_Del | c.4970delN | p.Phe1657SerfsTer5 | p.F1657Sfs*5 | O00443 | protein_coding | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
PIK3C2A | insertion | In_Frame_Ins | novel | c.1373_1374insCACAGGAATACATAGTTGCCTATGGCAAAG | p.Val458_His459insThrGlyIleHisSerCysLeuTrpGlnArg | p.V458_H459insTGIHSCLWQR | O00443 | protein_coding | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |||
PIK3C2A | deletion | Frame_Shift_Del | novel | c.2064delN | p.Phe688LeufsTer22 | p.F688Lfs*22 | O00443 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
PIK3C2A | deletion | Frame_Shift_Del | novel | c.1423delT | p.Cys475ValfsTer34 | p.C475Vfs*34 | O00443 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5286 | PIK3C2A | ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, TRANSPORTER | inhibitor | XL147 | PILARALISIB | |
5286 | PIK3C2A | ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, TRANSPORTER | inhibitor | BAY80-6946 | COPANLISIB | |
5286 | PIK3C2A | ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, TRANSPORTER | inhibitor | BYL719 | ALPELISIB | |
5286 | PIK3C2A | ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, TRANSPORTER | inhibitor | PI-103 | PI-103 | |
5286 | PIK3C2A | ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, TRANSPORTER | inhibitor | PF-4691502 | PF-04691502 | |
5286 | PIK3C2A | ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, TRANSPORTER | inhibitor | BKM120 | BUPARLISIB | |
5286 | PIK3C2A | ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, TRANSPORTER | inhibitor | GSK2636771 | GSK-2636771 | |
5286 | PIK3C2A | ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, TRANSPORTER | inhibitor | PX-866 | SONOLISIB | |
5286 | PIK3C2A | ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, TRANSPORTER | inhibitor | BGJ398 | INFIGRATINIB | |
5286 | PIK3C2A | ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, TRANSPORTER | inhibitor | PKI-587 | GEDATOLISIB |
Page: 1 2 |